AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04363749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint
Description: the fraction of inspired oxygen is reduced from \~21% (room air) to 14.3 and 12.7% allowing the SpO2 to decrease to \~75%, rebreathing test allowing the PCO2 to rise to 65 mmHg, inspiratory mechanical constraint with 50 to 75% of maximum inspiratory pressure
Study NCT04363749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint
Description: the fraction of inspired oxygen is reduced from \~21% (room air) to 14.3 and 12.7% allowing the SpO2 to decrease to \~75%, rebreathing test allowing the PCO2 to rise to 65 mmHg, inspiratory mechanical constraint with 50 to 75% of maximum inspiratory pressure
Study NCT04637126 — intervention group
Intervention type: OTHER
Intervention: Cardiac output measurement by transpulmonary thermodilution and transthoracic echocardiography
Description: Cardiac output is measured for all patients with transpulmonary thermodilution TPTD and transthoracic echocardiography TTE according to the recommendations
Study NCT02701231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency Rotating Magnetic Therapy System
Description: Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.
Study NCT02701231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic anti-tumor therapy
Description: Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
Study NCT02701231 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Systemic anti-tumor therapy
Description: Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
Study NCT02701231 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low-frequency Rotating Magnetic Therapy System
Description: Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
Study NCT03071328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue-M 200
Description: Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
Study NCT03558555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Intravenous saline
Study NCT02823600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RetinaVue 100 camera
Description: Images of the subject's eye will be obtained using the RetinaVue 100 camera and uploaded to a secure network. The study doctor, a board-certified ophthalmologist, will interpret the patient images and return a diagnosis and management plan to the dialysis unit.
Study NCT02537483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-120 Component A
Description: Comparator Product: IDP-120 Component A
Study NCT06716762 — intervention group
Intervention type: PROCEDURE
Intervention: Open Surgery
Description: Open cyst excision and Roux-en-Y hepaticojejunostomy performed through a 10 cm incision
Study NCT06716762 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Surgery
Description: Laparoscopic cyst excision and Roux-en-Y hepaticojejunostomy performed through small incisions with a laparoscope
Study NCT02028754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Carboxymethylcellulose
Description: Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.
Study NCT02028754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
Study NCT02028754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
Study NCT02028754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
Study NCT02028754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
Study NCT01646307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT01646307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Study NCT01646307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Study NCT01950975 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peripheral blood samples in EDTA tubes
Study NCT01950975 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsies
Study NCT04456530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aveed 750 MG in 3 ML IM Injection
Description: Participants in the Testosterone Group will receive two IM Aveed injections 1 month apart.
Study NCT04456530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 3 ML IM Injection
Description: Participants in the Control Group will receive two IM normal saline injections 1 month apart.
Study NCT03555916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX®, Allergan
Description: 50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
Study NCT03555916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
Study NCT05009654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Study NCT05009654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-leucine
Study NCT05009654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-leucine
Study NCT00190671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
Study NCT00190671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
Study NCT02537483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-120 Component B
Description: Comparator Product: IDP-120 Component B
Study NCT02537483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-120 Vehicle Gel
Description: Comparator Product: IDP-120 Vehicle Lotion
Study NCT03757572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alginate dressings
Description: The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Alginate dressings with silver and high-G cellulose will be applied to the wound. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials, will be also placed.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried.
Study NCT03757572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple gauze dressings
Description: The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Simple gauze dressings will be applied to the wound.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried.
Study NCT01724242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal DHEA
Study NCT01724242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01828775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: palliative care
Description: Receive early PCI
Study NCT01828775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: palliative care
Description: Receive delayed PCI
Study NCT01828775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01828775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study NCT04434677 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionation
Description: 3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
Study NCT04434677 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ultraHypofractionation
Description: 3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
Study NCT01697969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.2%
Study NCT02190643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation counseling with adherence focus
Study NCT00956215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: 80 mg tablet of Aprepitant with 50 ml of water 30 minutes before surgery
Study NCT00956215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aprepitant placebo
Description: 80 mg placebo tablet with 50 ml of water no later than 30 minutes before induction of anesthesia.
Study NCT02190643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cessation counseling without adherence focus
Study NCT02087124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Different amounts of whey protein dissolved in 200 mL water.
Study NCT05290324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam infusion will be given after the surgery as 0.25 mg/kg/min.
Study NCT03282734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.)
Description: Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for more than 30 minutes per a day for 4 weeks
Study NCT03282734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional home rehabilitation exercise
Description: Conventional home rehabilitation exercise for more than 30 minutes per a day for 4 weeks
Study NCT05089929 — intervention group
Intervention type: DEVICE
Intervention: Endoflip 2.0
Description: FLIP topography (Endoflip 2.0) analysis will be performed on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.
Study NCT05089929 — intervention group
Intervention type: PROCEDURE
Intervention: High Resolution Manometry
Description: All patients undergoing routine evaluation for gastroesophageal reflux disease will undergo high resolution manometry (HRM) testing.
Study NCT03380533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine 10mg transdermal patch used during the first five postoperative days after arthroscopic rotator cuff repair
Study NCT03380533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: Adhesive patch with the same macroscopic characteristics to the buprenorphine patch, without drugs.
Study NCT00503542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terazol or oral fluconazole for candidal vaginitis
Description: Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
Study NCT00503542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazol or oral fluconazole for candidal vaginitis
Description: Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
Study NCT03380533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Oral Scheme
Description: Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)
Study NCT01561989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO
Study NCT03380533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 50mg tablet that the patient consumes every 8 hours during the first five days
Study NCT03380533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo tablet that the patient consumes every 8 hours during the first five days
Study NCT03330782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)
Study NCT03330782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)
Study NCT03515902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mouthguard
Description: mouthguard
Study NCT03515902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mouthguard with desensitizing toothpaste
Description: mouthguard with desensitizing toothpaste containing 8% arginine with calcium carbonate
Study NCT03828448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: - anti-CD 20 monoclonal antibody administered via IV infusion
Study NCT03828448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: - PI3K Delta Inhibitor oral daily dose
Study NCT04693338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04693338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04693338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive ICP tasks
Study NCT02037165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1026706
Description: Placebo tablet
Study NCT02037165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin hard capsule
Study NCT02037165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: BI 1026706 oral solution
Study NCT02037165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib hard capsule
Study NCT03126357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand Cigarette
Study NCT01561989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03126357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: FT21039 an electronic tobacco vapor product
Study NCT03126357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: FT21092 an electronic tobacco vapor product
Study NCT01561989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent influenza vaccine
Description: Given IM
Study NCT04304924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The personalized telephone based intervention
Description: The personalized telephone based intervention:~1. Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);~2. Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises.
Study NCT00503542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole or Clindamycin for Bacterial Vaginosis
Description: Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
Study NCT00503542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole or Clindamycin for Bacterial Vaginosis
Description: Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
Study NCT02161536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motus Cleansing System
Study NCT03758183 — intervention group
Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Study NCT01679483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FloSeal application
Description: At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
Study NCT03554655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Momentum app
Description: The Momentum system consists of a smartphone app (for the patient) and a web portal (for the provider). Information entered in the app by the patient will automatically be transferred to the web portal for the provider to see. While one goal of the system is to support SDM, the Momentum app is not a classic decision aid focusing on finding a choice to a one-off treatment decision. Instead, the Momentum app is an aid to support some of the underlying elements behind SDM such as collaboration with one's provider, awareness and eliciting of one's needs, preferences and values.
Study NCT04999735 — intervention group
Intervention type: BEHAVIORAL
Intervention: CHDR Monitoring Remotely (MORE)
Description: CHDR MORE is a highly customizable platform which allows remote monitoring of patients and trial subjects, data ingestion, and data management. The current infrastructure includes an Android app to unobtrusively collect data from smartphone sensors, and a connection to the Withings Health online platform to collect wearable data. Data is stored on a secure server in a structured data scheme ensuring clear data management processes, forming a prerequisite for comprehensive data analysis. The Android app enables data collection from multiple smartphone sensors (e.g. location data, accelerometer and ambient light) as well as phone usage logs (e.g. app usage, calls and texts).